澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

MESOBLAST LTD

2.880

-0.020-0.69%

成交量：190.66萬

成交額：549.89萬

市值：36.95億

市盈率：-22.73

高：2.930

開：2.870

低：2.850

收：2.900

52周最高：3.370

52周最低：1.515

股本：12.83億

流通股本：7.86億

量比：0.39

換手率：0.24%

股息：- -

股息率：- -

每股收益(TTM):-0.127

每股收益(LYR):-0.127

淨資產收益率：-18.95%

總資產收益率：-5.37%

市淨率：4.13

市盈率(LYR):-22.73

資料載入中...

總覽公司新聞資訊公告

概念

新冠治療股-0.08%

醫藥生物股-0.33%

資金流向

資金流入：

資金流出：

新聞資訊

獨立研究在美國血液學會年會上提出，Remestemcel-L在治療SR-Agvhd的臨牀效果上優於Ruxolitinib

異動解讀 | Mesoblast股價盤中大漲6.72%，預計季度收入超3000萬美元

Mesoblast Limited - 預計2025年12月31日季度毛收入超過3000萬美元，來自Ryoncil的銷售

Mesoblast宣佈James M. O’Brien被任命為首席財務官

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hant/stock/MSB.AU"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MSB.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","market":"AU","secType":"STK","nameCN":"MESOBLAST LTD","latestPrice":2.88,"timestamp":1766466720000,"preClose":2.9,"halted":0,"volume":1906563,"delay":0,"nameEN":"MESOBLAST LTD","floatShares":786490638,"shares":1282967187,"eps":-0.1267231578332437,"marketStatus":"已收盤","change":-0.02,"latestTime":"12-23 16:12:00 AEDT","open":2.87,"high":2.93,"low":2.85,"amount":5498888,"amplitude":0.027586,"askPrice":2.89,"askSize":3152,"bidPrice":2.88,"bidSize":10000,"shortable":3,"etf":0,"ttmEps":-0.1267231578332437,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1766530800000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":2.9,"openAndCloseTimeList":[[1766444400000,1766466000000]],"volumeRatio":0.393509,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","floatShares":786490638,"roa":"-5.37%","roe":"-18.95%","lyrEps":-0.126677,"volumeRatio":0.393509,"shares":1282967187,"dividePrice":0,"high":2.93,"amplitude":0.027586,"preClose":2.9,"low":2.85,"week52Low":1.515,"pbRate":"4.13","psRate":"143.43","week52High":3.37,"institutionHeld":0,"latestPrice":2.88,"committee":0.520681,"eps":-0.1267231578332437,"divideRate":0,"volume":1906563,"delay":0,"ttmEps":-0.1267231578332437,"open":2.87,"prevYearClose":3.1,"prevWeekClose":2.91,"prevMonthClose":2.71,"prevQuarterClose":2.37,"fiveDayClose":2.77,"twentyDayClose":2.38,"sixtyDayClose":2.37,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MSB.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-26","symbol":"MSB.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MSB.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MSB.AU\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1100916668","title":"獨立研究在美國血液學會年會上提出，Remestemcel-L在治療SR-Agvhd的臨牀效果上優於Ruxolitinib","url":"https://stock-news.laohu8.com/highlight/detail?id=1100916668","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100916668?lang=zh_tw&edition=fundamental","pubTime":"2025-12-12 07:26","pubTimestamp":1765495606,"startTime":"0","endTime":"0","summary":"独立研究在美国血液学会年会上提出，Remestemcel-L在治疗SR-Agvhd的临床效果上优于Ruxolitinib","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","MSB.AU","BK7501"],"gpt_icon":0},{"id":"1115028816","title":"異動解讀 | Mesoblast股價盤中大漲6.72%，預計季度收入超3000萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1115028816","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115028816?lang=zh_tw&edition=fundamental","pubTime":"2025-11-26 07:03","pubTimestamp":1764111792,"startTime":"0","endTime":"0","summary":"澳大利亚生物技术公司Mesoblast Limited今日盘中股价大涨6.72%，引起投资者广泛关注。此轮涨势主要源于公司发布的积极财务预期。Mesoblast预计截至2025年12月31日的季度毛收入将超过3000万美元，这一收入主要来自其重磅产品Ryoncil的销售。Ryoncil是Mesoblast的主打产品，用于治疗急性移植物抗宿主病。该产品的强劲销售表现不仅直接提升了公司的财务状况，也增强了投资者对Mesoblast长期发展前景的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MSB.AU"],"gpt_icon":0},{"id":"1109683405","title":"Mesoblast Limited - 預計2025年12月31日季度毛收入超過3000萬美元，來自Ryoncil的銷售","url":"https://stock-news.laohu8.com/highlight/detail?id=1109683405","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109683405?lang=zh_tw&edition=fundamental","pubTime":"2025-11-25 22:45","pubTimestamp":1764081909,"startTime":"0","endTime":"0","summary":"Mesoblast Limited - 预计2025年12月31日季度毛收入超过3000万美元，来自Ryoncil的销售","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7501","MSB.AU","BK7067","MESO","BK4139"],"gpt_icon":0},{"id":"1182398223","title":"Mesoblast宣佈James M. O’Brien被任命為首席財務官","url":"https://stock-news.laohu8.com/highlight/detail?id=1182398223","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182398223?lang=zh_tw&edition=fundamental","pubTime":"2025-11-17 16:14","pubTimestamp":1763367269,"startTime":"0","endTime":"0","summary":"11月17日 - Mesoblast Ltd：James M. O’Brien被任命为Mesoblast的首席财务官。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7508","BK7067","MSB.AU"],"gpt_icon":0}],"pageSize":4,"totalPage":3,"pageCount":1,"totalSize":11,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/MSB.AU\",params:#limit:6,delay:true,,,undefined,":[{"market":"AU","name":"新冠治療股","bkCode":"BK7501","id":"package_au_concept_xgzlg","changeRate":-0.00079},{"market":"AU","name":"醫藥生物股","bkCode":"BK7508","id":"package_au_concept_yyswg","changeRate":-0.003303}]}}